vs

Side-by-side financial comparison of INNOSPEC INC. (IOSP) and PROASSURANCE CORP (PRA). Click either name above to swap in a different company.

INNOSPEC INC. is the larger business by last-quarter revenue ($455.6M vs $269.6M, roughly 1.7× PROASSURANCE CORP). PROASSURANCE CORP runs the higher net margin — 12.4% vs 10.4%, a 2.0% gap on every dollar of revenue. On growth, INNOSPEC INC. posted the faster year-over-year revenue change (-2.4% vs -7.1%). Over the past eight quarters, PROASSURANCE CORP's revenue compounded faster (-2.7% CAGR vs -4.6%).

Innospec Inc., formerly known as Octel Corporation and Associated Octel Company, Ltd., is an American specialty chemical company. It comprises three business units:The Performance Chemicals business trades in the personal care, home care, agrochemical, mining and industrial markets. The Fuel Specialties business specializes in manufacturing and supplying fuel additives. The Oilfield Services business supplies drilling, completion and production chemicals.

ProAssurance Corporation, headquartered in Birmingham, Alabama, is a property and casualty company that sells professional liability insurance to doctors. The company was founded in 1976 as Mutual Assurance and was later renamed to Medical Assurance in 1997. The name "ProAssurance" was created in 2001 when Medical Assurance merged with Professionals Group. The company is currently the fourth largest medical professional liability insurance writer and has over $6 billion in assets.

IOSP vs PRA — Head-to-Head

Bigger by revenue
IOSP
IOSP
1.7× larger
IOSP
$455.6M
$269.6M
PRA
Growing faster (revenue YoY)
IOSP
IOSP
+4.7% gap
IOSP
-2.4%
-7.1%
PRA
Higher net margin
PRA
PRA
2.0% more per $
PRA
12.4%
10.4%
IOSP
Faster 2-yr revenue CAGR
PRA
PRA
Annualised
PRA
-2.7%
-4.6%
IOSP

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IOSP
IOSP
PRA
PRA
Revenue
$455.6M
$269.6M
Net Profit
$47.4M
$33.4M
Gross Margin
28.0%
Operating Margin
10.3%
17.3%
Net Margin
10.4%
12.4%
Revenue YoY
-2.4%
-7.1%
Net Profit YoY
167.3%
106.4%
EPS (diluted)
$1.90
$0.65

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IOSP
IOSP
PRA
PRA
Q4 25
$455.6M
$269.6M
Q3 25
$441.9M
$279.6M
Q2 25
$439.7M
$276.8M
Q1 25
$440.8M
$272.1M
Q4 24
$466.8M
$290.1M
Q3 24
$443.4M
$285.3M
Q2 24
$435.0M
$290.4M
Q1 24
$500.2M
$284.7M
Net Profit
IOSP
IOSP
PRA
PRA
Q4 25
$47.4M
$33.4M
Q3 25
$12.9M
$1.4M
Q2 25
$23.5M
$21.9M
Q1 25
$32.8M
$-5.8M
Q4 24
$-70.4M
$16.2M
Q3 24
$33.4M
$16.4M
Q2 24
$31.2M
$15.5M
Q1 24
$41.4M
$4.6M
Gross Margin
IOSP
IOSP
PRA
PRA
Q4 25
28.0%
Q3 25
26.4%
Q2 25
28.0%
Q1 25
28.4%
Q4 24
29.2%
Q3 24
28.0%
Q2 24
29.2%
Q1 24
31.1%
Operating Margin
IOSP
IOSP
PRA
PRA
Q4 25
10.3%
17.3%
Q3 25
1.3%
1.6%
Q2 25
7.8%
9.9%
Q1 25
9.6%
-2.3%
Q4 24
8.8%
6.5%
Q3 24
10.3%
7.4%
Q2 24
9.4%
6.2%
Q1 24
10.1%
1.9%
Net Margin
IOSP
IOSP
PRA
PRA
Q4 25
10.4%
12.4%
Q3 25
2.9%
0.5%
Q2 25
5.3%
7.9%
Q1 25
7.4%
-2.1%
Q4 24
-15.1%
5.6%
Q3 24
7.5%
5.8%
Q2 24
7.2%
5.3%
Q1 24
8.3%
1.6%
EPS (diluted)
IOSP
IOSP
PRA
PRA
Q4 25
$1.90
$0.65
Q3 25
$0.52
$0.03
Q2 25
$0.94
$0.42
Q1 25
$1.31
$-0.11
Q4 24
$-2.80
$0.32
Q3 24
$1.33
$0.32
Q2 24
$1.24
$0.30
Q1 24
$1.65
$0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IOSP
IOSP
PRA
PRA
Cash + ST InvestmentsLiquidity on hand
$292.5M
$36.5M
Total DebtLower is stronger
$420.4M
Stockholders' EquityBook value
$1.3B
$1.3B
Total Assets
$1.8B
$5.4B
Debt / EquityLower = less leverage
0.31×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IOSP
IOSP
PRA
PRA
Q4 25
$292.5M
$36.5M
Q3 25
$270.8M
$54.5M
Q2 25
$266.6M
$41.6M
Q1 25
$299.8M
$43.5M
Q4 24
$289.2M
$54.9M
Q3 24
$303.8M
$45.3M
Q2 24
$240.2M
$36.9M
Q1 24
$270.1M
$65.4M
Total Debt
IOSP
IOSP
PRA
PRA
Q4 25
$420.4M
Q3 25
$421.5M
Q2 25
$422.6M
Q1 25
$423.7M
Q4 24
$424.9M
Q3 24
$425.9M
Q2 24
$426.9M
Q1 24
$427.8M
Stockholders' Equity
IOSP
IOSP
PRA
PRA
Q4 25
$1.3B
$1.3B
Q3 25
$1.3B
$1.3B
Q2 25
$1.3B
$1.3B
Q1 25
$1.3B
$1.2B
Q4 24
$1.2B
$1.2B
Q3 24
$1.2B
$1.2B
Q2 24
$1.2B
$1.1B
Q1 24
$1.2B
$1.1B
Total Assets
IOSP
IOSP
PRA
PRA
Q4 25
$1.8B
$5.4B
Q3 25
$1.8B
$5.6B
Q2 25
$1.8B
$5.5B
Q1 25
$1.8B
$5.5B
Q4 24
$1.7B
$5.6B
Q3 24
$1.8B
$5.7B
Q2 24
$1.7B
$5.6B
Q1 24
$1.7B
$5.7B
Debt / Equity
IOSP
IOSP
PRA
PRA
Q4 25
0.31×
Q3 25
0.32×
Q2 25
0.33×
Q1 25
0.34×
Q4 24
0.35×
Q3 24
0.35×
Q2 24
0.38×
Q1 24
0.38×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IOSP
IOSP
PRA
PRA
Operating Cash FlowLast quarter
$61.4M
$-25.6M
Free Cash FlowOCF − Capex
$46.8M
FCF MarginFCF / Revenue
10.3%
Capex IntensityCapex / Revenue
3.2%
Cash ConversionOCF / Net Profit
1.30×
-0.77×
TTM Free Cash FlowTrailing 4 quarters
$88.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IOSP
IOSP
PRA
PRA
Q4 25
$61.4M
$-25.6M
Q3 25
$39.3M
$27.2M
Q2 25
$9.3M
$-28.1M
Q1 25
$28.3M
$-11.6M
Q4 24
$25.7M
$-10.7M
Q3 24
$73.5M
$14.0M
Q2 24
$4.7M
$-12.8M
Q1 24
$80.6M
$-11.6M
Free Cash Flow
IOSP
IOSP
PRA
PRA
Q4 25
$46.8M
Q3 25
$25.0M
Q2 25
$-3.7M
Q1 25
$19.9M
Q4 24
$13.6M
Q3 24
$65.8M
Q2 24
$-6.2M
Q1 24
$69.9M
FCF Margin
IOSP
IOSP
PRA
PRA
Q4 25
10.3%
Q3 25
5.7%
Q2 25
-0.8%
Q1 25
4.5%
Q4 24
2.9%
Q3 24
14.8%
Q2 24
-1.4%
Q1 24
14.0%
Capex Intensity
IOSP
IOSP
PRA
PRA
Q4 25
3.2%
Q3 25
3.2%
Q2 25
3.0%
Q1 25
1.9%
Q4 24
2.6%
Q3 24
1.7%
Q2 24
2.5%
Q1 24
2.1%
Cash Conversion
IOSP
IOSP
PRA
PRA
Q4 25
1.30×
-0.77×
Q3 25
3.05×
18.81×
Q2 25
0.40×
-1.28×
Q1 25
0.86×
Q4 24
-0.66×
Q3 24
2.20×
0.85×
Q2 24
0.15×
-0.83×
Q1 24
1.95×
-2.52×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IOSP
IOSP

Refinery And Performance$147.0M32%
Personal Care$99.7M22%
Oilfield Services$93.1M20%
Other Fuel Specialties$47.1M10%
Other Performance Chemicals$40.0M9%
Home Care$28.7M6%

PRA
PRA

Workers Compensation Insurance Segment$164.4M61%
Other$59.6M22%
Segregated Portfolio Cell Reinsurance$45.7M17%

Related Comparisons